Industry Insider: Alcon’s Dr. Terry Kim

Terry Kim, MD, discusses his roles as CMO and head of global medical safety at Alcon, why and how he moved in this direction with his career, the Unity Vitreoretinal Cataract and Unity Cataract Systems, and more.

March 1, 2025
6 min

Ophthalmology Management

Objective:

To discuss Dr. Terry Kim's roles at Alcon and the impact of new ophthalmic technologies, including the Unity Vitreoretinal Cataract System and Voyager DSLT laser therapy.

Key Findings:

Unity systems received FDA 510(k) clearance in 2024, enhancing cataract surgery efficiency and potentially improving patient outcomes.
Voyager DSLT aims to simplify glaucoma laser therapy, improving patient experience by allowing patients to remain seated during the procedure.
New gas delivery systems streamline procedures and enhance accuracy in ophthalmic surgeries, addressing previous inefficiencies.

Interpretation:

Dr. Kim's insights highlight the importance of integrating clinical experience into product development to address unmet needs in eye care.

Limitations:

The article does not provide quantitative data on the effectiveness of the new systems, limiting the assessment of their impact.
Feedback from user evaluations is mentioned but lacks specific examples or details.

Conclusion:

Dr. Kim's leadership at Alcon aims to bridge clinical practice with innovative solutions in ophthalmology, drawing on his extensive clinical experience.

Industry Insider: Alcon’s Dr. Terry Kim

Objective:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Original Source(s)

Industry Insider: Alcon’s Dr. Terry Kim

Related Content

CSO Meeting 2026 Highlights Convergence of Innovation and Clinical Practice

Thirty Years Together in a Career Defined by Change

The Art of Ophthalmology 2026